Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 1,177 shares, a growth of 97.5% from the May 14th total of 596 shares. Based on an average daily volume of 10,593 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.
Wall Street Analyst Weigh In
AAPG has been the subject of several recent research reports. BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. Finally, B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday. They issued a “buy” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $46.43.
Check Out Our Latest Analysis on AAPG
Ascentage Pharma Group International Stock Up 2.9%
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter. On average, equities analysts forecast that Ascentage Pharma Group International will post -0.96 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Ascentage Pharma Group International
A number of large investors have recently made changes to their positions in AAPG. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International during the 3rd quarter worth $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the 2nd quarter worth $391,000. XY Capital Ltd increased its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the period. Finally, UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the period.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
